Date: 2020-02-26

Type of information: Research agreement

Compound: new targets associated with age-related macular degeneration

Company: Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG)

Therapeutic area: Ophthalmological diseases - Cardiovascular diseases

Type agreement: R&D

Action mechanism:

Disease: Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy


  • • On February 26, 2020, Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD.
  • Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients diagnosed with polypoidal choroidal vasculopathy (PCV). This approach will leverage Gemini’s experience using precision medicine to develop potential therapeutics for genetically defined patient populations. Gemini will use this information to increase its understanding of the links between genetic variants, the impact on the expression of specific genes, and the diagnosis of PCV. PCV and AMD are related diseases, and there are shared genetic causes between the two conditions. This collaboration will inform future development of more targeted therapies for both conditions.

Financial terms:

Latest news:

Is general: Yes